A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease who Failed Prior Biologic Treatment @ Long Island Clinical Research Associates

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Crohn's Disease
  • Age: Between 18 years - 80 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Male or female aged >=18 to <= 80 years at the Baseline Visit. Confirmed diagnosis of Crohn’s Disease (CD) for at least 3 months prior to Baseline.
    2. Demonstrated intolerance or inadequate response to one or more biologic therapies.

You may not be eligible for this study if the following are true:

    1. Subject with a current diagnosis of Ulcerative Colitis (UC)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.